Bio-Rad Laboratories, Inc. (BIO) stock analysis

Healthcare · Medical Devices

From the 10-K filed 2026-02-13

How it makes money

Bio-Rad earns revenue by selling instruments, reagents, and consumables across life science research and clinical diagnostics markets worldwide.

Bio-Rad operates through two primary segments: Life Science and Clinical Diagnostics. The Life Science segment generates roughly 40% of consolidated net sales by providing tools used to separate, purify, and analyze biological materials in research and biopharmaceutical settings. The Clinical Diagnostics segment produces the remaining 60% of sales by supplying diagnostic test systems, kits, and quality controls to hospital and reference laboratories.

Revenue in the diagnostics business is largely recurring. Because clinical laboratories standardize their workflows on specific testing platforms, an initial instrument placement generates ongoing, predictable sales of proprietary reagents and consumables for each sample processed.

What protects it: the moat

Management claims that specialized scientific knowledge and long-term customer relationships protect its market position against competitors.

Bio-Rad holds thousands of patents and trademarks, but management asserts that the company's ability to develop and manufacture products depends primarily on proprietary knowledge, technology, and specialized skills rather than formal intellectual property positions.

To maintain customer loyalty, the company relies on an extensive direct commercial organization of experienced, scientifically trained sales professionals. This direct sales model is designed to foster deep customer engagement and secure long-term relationships across global research and healthcare institutions.

What growth costs

The filing does not disclose the specific capital expenditures, research and development budgets, or working capital outlays required to maintain and grow earnings.

While Bio-Rad discusses the operational activities required to run its business, such as maintaining a global supply chain, employing direct sales personnel, and navigating international regulatory compliance, the text omits specific financial figures for ongoing maintenance capital expenditures or exact annual research and development investments.

What could damage it

Aggressive pricing in multi-year public tenders could force Bio-Rad to lower prices or lose key contracts, permanently impairing diagnostic revenue.

Governments and large healthcare institutions frequently utilize public tenders to procure diagnostic equipment and consumables, and these tenders are increasingly structured as multi-year commitments. Because the total value of these long-term contracts is exceptionally high, competitors have become more aggressive with their pricing strategies. If Bio-Rad cannot match these competitive bids or absorb higher underlying costs without full price recovery, it risks losing major customer accounts, which would directly erode its high-margin recurring revenue base.

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Other companies in Medical Devices